Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome

Acute Leukemia Clinical Trial

Official title:

Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01314599
• Other study ID #: PM1183-A-002-10
• Status: Completed
• Phase: Phase 1
• First received: March 9, 2011
• Last updated: November 4, 2015
• Start date: May 2011
• Est. completion date: July 2015

Study information

• Verified date: July 2015
• Source: PharmaMar
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.

Description:

Open-Label, Dose-Escalating, Clinical and Pharmacokinetic Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered as 1-hour intravenous (i.v.) infusion on three consecutive days (Days 1-3) to patients with advanced acute leukemia and to assess the safety profile and tolerability, to obtain preliminary information on the efficacy and to characterize the pharmacokinetics (PK) and pharmacogenomic (PGx) profile of PM01183.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: July 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Voluntarily signed and dated written informed consent

• Age = 18 years.

• Patients must have a previous cytological or histological diagnosis of:

• Relapsed or primary refractory non-M3 acute myeloid leukemia (AML) by the World Health Organization (WHO) criteria (irrespective of the number of prior regimens), either de novo or secondary [i.e., secondary to myelodysplastic syndromes (MDS), myeloproliferative neoplasms or previous chemotherapy for another condition].

• Untreated AML in patients = 65 years of age, if patients are not candidates for standard induction chemotherapy or have poor risk AML (i.e., secondary AML or AML with adverse cytogenetics or complex karyotype).

• Accelerated or blastic phase chronic myeloid leukemia (CML, with progressive disease despite treatment with BCR-ABL kinase inhibitors), or chronic myelomonocytic leukemia (CMML).

• Relapsed or refractory acute lymphoblastic leukemia (ALL) by WHO criteria.

• Patients must have the following laboratory values prior to the start of treatment:

• Total bilirubin = 1.5 x upper limit of normal (ULN) range of values, unless due to elevated indirect bilirubin (e.g.,Gilbert's syndrome or hemolysis).

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 x ULN.

• Alkaline phosphatase (AP) = 2.5 x ULN.

• Albumin = 2.5 g/dl.

• Calculated creatinine clearance (CrCl) = 30 ml/min (using Cockcroft and Gault's formula).

• Creatine phosphokinase (CPK) = 2.5 x ULN.

• Eastern Cooperative Oncology Group (ECOG) Performance Status = 2.

• Negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

• Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods throughout the treatment period and for six months after discontinuation of treatment.

• Patients who plan to undergo allogeneic BM transplantation within four weeks.

• Other relevant diseases or adverse clinical conditions:

• History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.

• Symptomatic or unstable cardiac arrhythmias, and/or prolonged QT-QTc grade = 2.

• History of significant neurological or psychiatric disorders that may affect the patient's compliance with the protocol assessments.

• Active uncontrolled infection.

• Myopathy or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 x ULN in two different determinations performed one week apart).

• Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

• Any other major illness that, in the Investigator's judgment, will substantially increase the risk associated with the patient's participation in this study.

• Hematopoietic allogeneic stem cell transplantation within the last four months and/or active graft versus host disease, or prior autologous transplantation within the last four weeks.

• Patients known to be human immunodeficiency virus (HIV) positive.

• Cytotoxic chemotherapy within the last two weeks; radiation therapy within the last two weeks; biologic agents, including hematopoietic growth factors, within the last week; hydroxyurea, imatinib, corticosteroids and arsenic trioxide should be discontinued at least 24 hours prior to first study drug administration.

• Treatment with any investigational product in the = 5 half-lives period prior to inclusion in the study, or 30 days after therapy (in case of unknown half-life), unless evidence of rapid proliferating disease and upon discussion with the Sponsor.

• Known hypersensitivity to any of the components of the drug product (DP).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Acute Disease
• Acute Leukemia
• Leukemia
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion
PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial. Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
PharmaMar

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) and Recommended Dose (RD) of PM01183 in patients with advanced acute leukemia.	The recommended dose (RD) will be the immediate lower DL below the MTD (maximum tolerated dose)with less than 1/3 of the first 6 evaluable patients experiencing DLT (dose limiting toxicity)during the induction, provided the RD is = dose level 2. If the RD is determined at dose level 1, no further expansion will be done, and the study will be terminated.	Up to 30 months	Yes
Secondary	Antileukemic activity	Activity will be defined according to the International Working Group (IWG) criteria.	After induction/reinduction and every 4 weeks after treatment discontinuation; up to 30 months	No
Secondary	Pharmacogenomic (PGx) profile of PM01183 in patients with advanced acute leukemia.	Identification of potential biomarkers of response to PM01183	Between day -24 to day 1	No
Secondary	Pharmacokinetics (PK) of PM01183 in patients with advanced acute leukemia	The PK will be elucidated using standard non-compartmental methods. The following parameters will be calculated: maximum drug concentration (Cmax), area under the curve (AUC), volume of distribution based on the terminal half-life (Vz), volume of distribution at steady state (Vss), clearance (CL) and half-life (t1/2)	Days 1 to 8 of induction and day 1 of next phase	No